HC Wainwright Reaffirms “Buy” Rating for Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma (NASDAQ:TBPH)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They currently have a $15.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 82.04% from the company’s current price.

Other equities research analysts also recently issued reports about the stock. Leerink Partnrs downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 6th. TD Cowen cut their price target on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. StockNews.com cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. Finally, Leerink Partners lowered Theravance Biopharma from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $15.00 to $10.00 in a research report on Tuesday, August 6th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $13.75.

Theravance Biopharma Stock Performance

Shares of TBPH opened at $8.24 on Monday. Theravance Biopharma has a 52 week low of $7.44 and a 52 week high of $11.71. The stock has a market capitalization of $400.74 million, a price-to-earnings ratio of -9.58 and a beta of 0.24. The stock has a fifty day moving average of $8.76 and a 200-day moving average of $8.87.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.25). Theravance Biopharma had a negative net margin of 73.61% and a negative return on equity of 21.29%. The firm had revenue of $14.26 million during the quarter, compared to the consensus estimate of $15.81 million. During the same quarter in the prior year, the business posted ($0.28) earnings per share. As a group, equities analysts forecast that Theravance Biopharma will post -1.04 EPS for the current year.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 335,965 shares in the company, valued at approximately $3,023,685. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now directly owns 335,965 shares of the company’s stock, valued at approximately $3,023,685. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Eli Samaha bought 999,800 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The shares were acquired at an average price of $7.80 per share, for a total transaction of $7,798,440.00. Following the transaction, the insider now owns 9,511,150 shares in the company, valued at $74,186,970. The disclosure for this purchase can be found here. Corporate insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

Several large investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. grew its stake in shares of Theravance Biopharma by 66.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,583 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 3,824 shares during the period. Hsbc Holdings PLC bought a new position in Theravance Biopharma in the second quarter worth approximately $108,000. Gerber LLC bought a new position in Theravance Biopharma in the fourth quarter worth approximately $112,000. XTX Topco Ltd acquired a new stake in Theravance Biopharma in the second quarter valued at approximately $129,000. Finally, State Board of Administration of Florida Retirement System increased its holdings in shares of Theravance Biopharma by 28.2% during the first quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 4,990 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.